Hope on the Horizon: Clinical Trials & Progress in Ocular/Uveal Melanoma

AIM at Melanoma, in collaboration with its Canadian partner, the Save Your Skin Foundation, is pleased to present this informative webinar on ocular/uveal melanoma.

Hosted by: Richard D. Carvajal, MD, Melanoma and Cutaneous Oncology, Early Drug Development, Northwell Health Cancer Institute

Featuring:

• Marcus Butler, MD, board- certified medical oncologist at the Princess Margaret Cancer Centre in Toronto, Canada and Assistant Professor at the University of Toronto
• Suthee Rapisuwon, MD, board-certified medical oncologist, medical geneticist, and hematologist at MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center
• Jose Lutzky, MD, triple board-certified hematologist and oncologist at Sylvester Comprehensive Cancer Center

For years, patients had few options beyond observation, but new advances are changing the landscape. In this discussion, you’ll learn about:

• The shift toward preventative and neoadjuvant therapies
• How BAP1 loss and gene expression profiling help identify high-risk patients
• Early trial results with requisinus that reduce relapse risk
• Promising outcomes from neoadjuvant + adjuvant immunotherapy
• The role of tebentafusp in preventing relapse
• Emerging tools like circulating tumor DNA (liquid biopsy) for monitoring

This webinar is essential for patients, caregivers, and clinicians interested in the future of ocular melanoma care.

Watch the full video below to explore these breakthroughs and learn what hope looks like in 2025 and beyond.